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Liver transplantation is the only recognized effective treatment for end-stage liver disease.
However, organ shortages have become the main challenge for patients and physicians
within the transplant community. Waiting list mortality remains an issue with around
10% of patients dying whilst waiting for an available organ. The post-transplantation
period is also associated with an adverse complication rate for these specific cohorts of
high-risk patients, particularly regarding patient and graft survival. Ischaemia reperfusion
injury (IRI) has been highlighted as the mechanism of injury that increases parenchymal
damage, which eventually lead to significant graft dysfunction and other poor outcome
indicators. The consequences of IRI in clinical practice such as reperfusion syndrome,
primary non-function of graft, allograft dysfunction, ischaemic biliary damage and
early biliary complications can be life-threatening. IRI dictates the development of a
significant inflammatory response that drives the pathway to eventual cell death. The
main mechanisms of IRI are mitochondrial damage due to low oxygen tension within
the hepatic micro-environment and severe adenosine triphosphate (ATP) depletion
during the ischaemic period. After the restoration of normal blood flow, this damage
is further enhanced by reoxygenation as the mitochondria respond to reperfusion by
releasing reactive oxygen species (ROS), which in turn activate Kupffer cells within
the hepatic micro-environment, leading to a pro-inflammatory response and eventual
parenchymal cell apoptosis and associated tissue degradation. Machine perfusion (MP)
is one emergent strategy considered to be one of the most important advances in organ
preservation, restoration and transplantation. Indeed, MP has the potential to rescue
frequently discarded organs and has been shown to limit the extent of IRI, leading
to suppression of the deleterious pro-inflammatory response. This immunomodulation
reduces the prevalence of allograft rejection, the use of immunosuppression therapy
and minimizes post-transplant complications. This review aims to update the current
knowledge of MP with a focus on normothermic machine liver perfusion (NMLP) and its
potential role in immune response pathways.
Keywords: normothermic machine liver perfusion, immune activation, hepatic microenvironment, graft survival,
liver transplantation
Parente et al. Immune Reaction in NMP
INTRODUCTION
Liver transplantation (LT) is the only effective and definitive
therapy for end stage liver disease. However, the increasing
disparity between the number of organ donors and the number
of wait-listed patients has become a constant challenge for the
transplant community worldwide, with an overall waiting list
mortality between 15 and 20% in the UK (1).
Based on these concerns, sub-optimal grafts, which are those
from “Extended Criteria Donors” (ECDs), have been used for
LT to ameliorate the difference between organ demand and
availability. There are limited guidelines on the use of these grafts
from ECDs, hence the numerous clinical trials being carried
out to review the viability and functionality they may possess.
ECDs are considered to be: (1) older aged (≥60 years old)
brain death donors (DBD), (2) donors (aged 50–59 years old)
with underlying medical co-morbidities(two of either stroke,
hypertension, or serum creatinine >1.5 mg/dL), (3) donors with
high-grade steatosis, and (4) cardiac death donors (DCD) or
donors whose liver is subjected to prolonged cold ischaemia time
(CIT). Historically, transplanted grafts from ECDs had poorer
graft outcomes including primary non-function (PNF), early
allograft dysfunction (EAD) and ischaemic cholangiopathy (2).
MP protocols from clinical trials such as Dual Hypothermic
Oxygenated Perfusion of DCD Liver Grafts (DHOPE) and
Consortium on Organ Preservation in Europe (COPE) project
have developed diverse methods to manipulate the immune
response and restore marginal organs to a state where they are
deemed transplantable. In this setting, the overall donor pool
could be expanded, which could lighten the burden on the
transplantation list and reduce waitlist mortality. This review
will look at normothermic machine perfusion (NMP) and its
effect on the immune reaction upon on the graft during the
transplantation phase.
THE RATIONALE OF ORGAN
PRESERVATION BY MACHINE PERFUSION
Static cold storage (SCS) has been the standard preservation
method for liver grafts pre-transplantation. The basis of this
preservation technique is inducing hypothermic conditions to
reduce cellular activity, theoretically reducing the consumption
of mitochondrial ATP substrate stores, increasing anaerobic
Abbreviations: CIT, Cold Ischemia Time; DAMPs, Damage Associated Molecular
Patterns; DBD, Donation after Brain Death; DCD, Donation after Cardiac
Death; DHOPE, Dual Hypothermic Oxygenated Perfusion; EAD, Early Allograft
Dysfunction; ECD, Extended Criteria Donors; HMP- Hypothermic Machine
Perfusion; HOPE- Hypothermic Oxygenated Perfusion; IFN, Interferon; IFOT,
Ischaemia Free Organ Transplantation; IL, Interleukin; IRI, Ischaemic Reperfusion
Injury; LT, Liver Transplantation; MAPCs, Multipotent Adult Progenitor Cells;
MP, Machine Perfusion; NLR, Nucleotide-binding Oligomerization Domain
(NOD)-like receptors; NMLP, Normothermic Machine Liver Perfusion; PAMPS,
Pathogen-Associated Molecular Patterns; PNF, Primary Non-Function; PRR,
Pathogen Recognition Receptor; RIG-I, Retinoic acid-Inducible Gene-I-like
receptors; ROS, Reactive Oxygen Species; SNMP, Subnormothermic Machine
Perfusion; TLR, Toll Like Receptors; TNF, Tumor Necrosis Factor; WIT, Warm
Ischaemia Time.
metabolism and leading to an increase in lactate production
within the parenchymal cells. Despite the fact that the liver
microenvironment is ordinarily hypoxic, a further hypoxic insult
is detrimental to hepatocytes. At low temperatures cells sustain
a basal activity that, in a hypoxic environment, induces ATP
depletion and lactic acid accumulation. Decreasing levels of ATP
induce cellular lysis via the loss of the normal electrolyte cell
membrane gradients, which triggers the activation of proteolytic
enzymes (3). Mitochondrial damage develops due to lack of
available metabolic substrates namely oxygen and ATP. This
is the metabolic pathway and underlying cause of ischaemia
reperfusion injury (IRI) (4). The period of oxygen deprivation,
and then the restoration of normal oxygenated blood flow
to the liver propagates the IRI cascade. After reperfusion the
mitochondria react by releasing all the toxins generated and
accumulated during the ischaemic period, which encompasses
the time from donor graft vessel clamp time to cold ischaemia
time. These toxins include the reactive oxygen species (ROS)
which activate pro-inflammatory cascades and, eventually, cell
apoptotic pathways (5–7).
Within the liver allograft, the oxygen deprivation that
provokes the release of damage associated molecular patterns
(DAMPs), such as HMGB-1, which promote the inflammatory
response by activating Antigen Presenting Cells (APCs), like
dendritic and resident immune cell subsets, Kupffer cells.
However, ECD livers have a lower tolerance of hypoxia, leading
to a more severe IRI and more serious clinical consequences,
such as reperfusion syndrome, allograft dysfunction, ischaemic
biliary damage and early biliary complications. There is currently
an array of new preservation methods with varied perfusate fluid
types andmachine perfusion methods in normothermic machine
perfusion. Nonetheless, hypothermic machine perfusion (HMP)
and subnormothermic machine perfusion (SNMP) play a
dynamic role in mediating the immune response in a number
of visceral organ transplantations including the kidneys, liver,
pancreas, intestine, heart and lung (8).
Machine perfusion (MP) has been key in preserving Donors
after Circulatory Death (DCD) allografts. MP has shown
promise in utilizing DCD kidneys for transplantation, with the
MP-preserved renal allografts performing better when compared
with simple cold storage (9–11). Taylor et al. highlighted the
significance of this result, with the aim to widen the renal donor
pool without fear of transplanting a graft susceptible to numerous
post-operative complications and adverse long-term outcomes.
There are some complications that occur more frequently in
the early post-transplant phase in the MP DCD kidney group,
including significantly higher incidences of early delayed graft
function and primary non-function cases when compared with
matched MP DBD donor grafts. However, on evaluation of long-
term outcomes, renal function in the MP DCD kidney group
recovers within 5–6 months post-transplantation, and both DCD
and DBD donor kidneys have equal serum creatinine levels at
this timepoint (12). Studies including Weissenbacher et al. have
demonstrated that prolonged perfusion whilst recirculating urine
in with the perfusate in order to maintain the composition of
the perfusate fluid has beneficial effects on the graft and ensures
stability of the perfusate (13).
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NMP in liver (NMLP) and renal grafts reduce peak creatinine,
improve graft survival, and allow organ recovery after periods
of cold ischaemia. The energy requirements that the graft
demands whilst being on NMPmeans that there is a requirement
for an oxygen carrier, oxygen, and nutrient supplementation
within the perfusion circuit to support physiological metabolic
rates. By doing so research groups have reduced the effect of
reperfusion tissue injury and subsequent graft dysfunction (14).
Hypothermic Machine Perfusion (HMP) has clearly been shown
to be advantageous in the preservation of both DBD and DCD
allografts of the liver, kidneys, and pancreas. HMP in renal
allografts lowers the incidence of poor clinical parameters in
sub-optimal grafts post-renal transplantation (15, 16). HMP use
has increased due to decreased Delayed Graft Function (DGF)
occurrence for ECD, DCD, and DBD donor kidneys (17). With
ECD, DCD, andDBD grafts, HMP allows an extensive review and
assessment of the renal organ prior to transplantation, according
to the “Predictive Score Model for Delayed Graft Function
Based on Hypothermic Machine Perfusion Variables in Kidney
Transplantation (18).”
There are similar studies of hypothermic machine perfusion
of the pancreases, that demonstrated reduced graft oedema and
reduced islet and acinar damage (19, 20). One study using
20 human pancreases in a hypothermic pulsatile perfusion of
marginal human pancreas-duodenum organs for 24 h showed
that this strategy was feasible with no deleterious parenchymal
effect (21). Further observations highlighted that the ideal
parameters for hypothermic continuous perfusion of pancreases
has been difficult to ascertain. Branchereau et al. demonstrated
that whilst using a hypothermic oxygenated continuous circuit at
25 mmHg for 24 h, none of the pancreas grafts used in the study
showed signs of, or produced markers of, cellular injury, oedema,
or necrosis. The tissue level of adenosine triphosphate (ATP)
is a long-established marker of graft viability and functionality
and is universal for all solid organ transplants (22). ATP is
also a marker of the viability of machine-perfusion treated
grafts (23). The Branchereau study highlighted that the tissue-
biopsies of the pancreases in the HMP-group had a higher
concentration of ATP levels when compared to the control
group (21, 24). The maintenance of low pulsatile perfusion
pressures in turn prevents endothelial damage and increased
vasculature thrombosis (24, 25). We see that the low pressures
and the pulsatile actionmay activate endothelial protective genes,
including Kruppel-like factor 2, which is overexpressed by the
endothelium during perfusion and has an antithrombotic action
and promotes effective local microcirculation (26).
Huang et al. (27) used sub-normothermic machine liver
perfusion (SNMLP) in whole and split liver NMLP. The study
highlighted that ATP generation during perfusion is a potential
viability marker that may be predictive of allograft function after
transplantation. The ATP:ADP and ATP:AMP ratios increased
similarly between split lobes and whole grafts within the first 2 h
and decreased slightly by the 3rd hour among both the whole
liver and split liver groups in this study. The increase of the
energy ratios is an important marker for good graft function. No
significant differences were seen when comparing left and right
lobes for the energy ratios during the split machine perfusion
model. This highlights the potential in the split technique, as we
can hypothesize that both lobes will behave metabolically and
physiologically in the same way (28). In essence, if each lobe
has good function, we are therefore able to further increase the
donor pool by utilizing what previously was one suboptimal liver
allograft into two viable transplantable allografts (27, 29, 30).
With improving viability of grafts on MP, research groups
often seek to use quantitative analysis of DAMPs (HMGB-
1, cfDNA, etc.) and PAMPs (Pathogen-Associated Molecular
Patterns) in tissue and perfusate as markers of graft restoration
and the dampening of intraparenchymal immune reactions
highlighted in various SNMP and HMP studies, such as the
Huang and Porte groups, respectively. For extended perfusion
and to improve graft function in most visceral allografts using
HMP, the circuit requires oxygenation. Transforming the HMP
into a hypothermic oxygenated perfusion further attenuates
the immune reaction in liver donor grafts during extended
MP restoration (31). Dual hypothermic oxygenated machine
perfusion (DHOPE), a new clinical preservation technique
developed by the Porte group, attempts to preserve donor liver
grafts of poorer quality for longer periods of time (24 h). This
facilitates transplantation by expanding the donor pool to include
both marginal and sub-marginal human and porcine livers. The
study highlighted that extended end-ischaemic DHOPE enabled
successful preservation of porcine and discarded human liver
grafts for up to 24 h (with required perfusion temperatures to be
remain between 8 and 10◦C) (31). Specific markers and cytokines
were measured to compare and quantify hepatocellular injury
and the production of deleterious pro-inflammatory cytokines.
Alanine aminotransferase (ALT), HMGB-1, and cell-free DNA
(cfDNA) (32) are markers used to detect and quantify nuclear
subcellular injury and cell damage with necrosis. Tumor necrosis
factor alpha (TNF-α) and interleukin 6 (IL-6) were markers
of initiation and development of a proinflammatory response
(33), whilst malondialdehyde (MDA) was used to detect lipid
peroxidation seen in oxidative stress. MDA was found in the
perfusate and the liver parenchyma during tissue sampling in
this study (34). DHOPE also quantified intracellular ATP as a
marker of the energy status and viability of the grafts pre- and
post-DHOPE (35).
ALT, HMGB-1, and cfDNA were not elevated by extended
DHOPE preservation in the perfusate for the livers after re-
warming. There were no histological necrotic changes in the
DHOPE group. Levels of MDA were not increased in liver
biopsies at the end of DHOPE (p = 0125) or at the end of
reperfusion (p = 0.604) when compared to the control static
cold storage group. Perfusate levels of HMGB-1, cfDNA, TNF-
α, and IL-6 remained low in both livers during the entire
period of DHOPE. The reduction in pro-inflammatory cytokines
downregulates chemokine and chemoattractant production,
which in turn dampens the immune reaction in the DHOPE
livers. Von Willebrand factor (vWF), a marker of endothelial
injury of the vasculature, was also not increased. vWF, DAMPs
and PAMPs are present in endothelial injury and endothelial
activation (26). Endothelial activation within inflamed allograft
vessels allows the binding of vWF followed by platelets.
This then promotes the opening of endothelial junctions and
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facilitates leucocyte transmigration to the site of liver injury
and inflammation, leading to immunothrombosis and potential
allograft demise. DAMPs generated are recognized by pathogen
recognition receptors (PRRs), such as Toll-like receptors (TLRs)
and cytoplasmic Nod-like receptors (NLRs), which drive an
immune response.
The immune cells such as mast cells, macrophages, dendritic
cells, innate lymphoid cells, and basophils recruited to site
of inflammation and injury by chemokines express PRRs on
their surface, sensing and binding with PAMPs and DAMPs.
PRR activation leads to the production of proinflammatory
cytokines including TNF-α, IL-1, vasoactive amines (e.g.,
histamine and serotonin), nitric oxide (NO), reactive oxygen
species (ROS), neuropeptides, and arachidonic acid metabolites
(e.g., prostaglandins and leukotrienes). This cascade of pro-
inflammatory cytokine production induces damage and
inflammation leading to the disruption of the integrity of macro-
and micro- endothelial barriers.
NMP and HMP diminish the progression of endothelial
damage and generation of DAMPs that drive a pro-inflammatory
immune reaction. Tietjen et al. (36) have shown that with
the use of ex vivo machine perfusion there are windows of
opportunity to deliver therapeutics to the organ directly. The
group targeted endothelial cells as their primary targets for
reducing ischaemic-reperfusion injury (IRI) in renal allografts
during NMP. Therapeutics have been developed to target
endothelial cell injury and improve long-term outcomes. The
group used nanoparticles (NP) to serve as a delivery mechanism
of key medications, using surface conjugation of an anti-CD31
antibody (also known as anti-platelet endothelial cell adhesion
molecule-1 (PECAM-1) antibody) to enhance targeting of NPs
to graft endothelial cells of human kidneys undergoing NMP.
Similar studies have also used NMP to deliver therapeutics
to reduce the immune response driven by IRI. Thompson
et al. used multi-potent adult progenitor cells (MAPCs)
to minimize IRI (37). MAPC-treated kidneys demonstrated
improved physiological parameters when compared to the
control group. Parameters including improved urine output
(p = 0.009), reduced expression of novel injury biomarker,
Neutrophil gelatinase-associated lipocalin, (NGAL) (p = 0.012),
and improved microvascular perfusion and down regulation
of pro-inflammatory cytokines. Laing et al. utilized NMLP
to deliver MAPCs, demonstrating that these MAPCs can be
delivered to the liver prior to host immune cell involvement and
with maintenance of continuous perfusion. The study showed
trans-endothelial migration of MAPCs into vasculature and
parenchymal endothelium. Whilst in the endothelium, MAPCs
secreted soluble factors that would have anti-inflammatory
and immunomodulatory benefits in a human model of liver
transplantation (38).
NORMOTHERMIC MACHINE PERFUSION
Early NMLP studies (39, 40) describe how perfusing the graft
at a physiological temperature has been revived and is at the
forefront of “bench to bedside” practice in transplantation.
In contrast to Simple cold storage (SCS) is a process by
which the preservation solution is infused into the organ
and then stored statically at hypothermic temperatures; the
principles of NMLP is to maintain physiological conditions by
supplementation of key metabolic substrates during perfusion
of the organ. This is obtained with inflow of human blood or
an oxygen-carrying blood substitute at 37◦C, which simulates
physiological conditions. In this environment, cell metabolism
is maintained thanks to normal oxygen tensions within the
perfusate, preventing ischaemic changes and providing the
substrate for ATP production. In this setting, feasibility and safety
were demonstrated and IRI and its consequences were shown to
be reduced (41–43).
The main features and potential appeal of NMLP is to offer
the possibility for assessing graft viability, for graft reconditioning
and for improving high-risk potential liver allografts (44). This
ability has been crucial, as many potentially transplantable
livers might otherwise be discarded if deemed suboptimal
without the means to recondition and improving the graft
function prior to assessing the grafts’ function in simulated
physiological conditions.
There are four NMLP devices that are available: the OrganOx
metra R© (OrganOx Ltd., Oxford, UK), the Liver Assist (Organ
Assist R©, Groningen, the Netherlands), the Cleveland circuit
(Cleveland Clinic, Cleveland, Ohio, US) and the OCSTM
Liver System (Transmedics, Andover, Massachusetts, US). The
mechanism of action is the same with four common main
components: an oxygenator, a blood reservoir, a pump that can
be single or double for hepatic artery and portal vein inflow and
a heat exchanger.
Early human application of NMLP in the UKwas documented
by the Birmingham Machine Perfusion Group (45–47). The
group compared outcomes of NMLP of DBDs and DCDs liver
allografts to a matched control SCS group: the first 20 patients
were transplanted with NMP primed grafts and described
adequate outcomes (48). No grafts in either arm of the trial
had primary non-function as a complication. Three patients’
grafts (15%), had early allograft dysfunction (EAD) in the NMLP
group compared to nine patients (23%) in the control SCS group.
Median intensive care unit and hospital stays were comparable
between the NMLP and SCS groups. Four DBD-NMLP patients
in the trial developed anastomotic biliary strictures, which were
treated with stenting. Patient survival at 1 year in the NMLP
group was 95%, with 1 death at 9 months accounted for by an
alcohol abuse relapse (46).
Bral et al. reported preliminary single-center North American
experience using the OrganOx metra R© device with nine liver
grafts, which were matched with SCS grafts (49). There was no
statistically significant difference in peak AST levels in the first
7 days in NMLP and SCS preserved grafts (p = 0.52), and there
was no statistically difference in bilirubin levels during the first 7
days between the groups (p= 0.35). There was also no statistically
significant difference in graft survival at 30 days in an intention-
to-treat analysis (p = 0.25). Intensive care and hospital stays
were higher in the NMLP group. This preliminary experience
demonstrates feasibility as well as the potential technical risks of
NMLP and highlights a need for larger, randomized studies with
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long-term follow up to assess functionality of NMP in the clinical
setting (50).
Nasralla et al. published the result of a large multinational,
open-label, two-arm, parallel randomized controlled trial on
NMLP versus SCS (50). The trial randomized 334 livers,
allocating 164 to SCS and 170 to NMLP using the NMLP
OrganOx metra R© device. Eventually, 101 SCS and 121 NMLP
were successfully transplanted. They reported that peak AST
levels during the first 7 days after LT were reduced by 49.4% in
the NMLP group compared to SCS when adjusted by center and
donor type (geometric mean ratio 0.506, 95% confidence interval
0.388–0.659; P < 0.001). There was one case of PNF in the NMLP
group, whereas no cases of PNF were reported in the SCS group.
EAD rates were available in 216 recipients: the odds of developing
EAD in the NMLP arm (12 out of 119) were 74% lower than
the SCS arm (29 out of 97; odds ratio 0.263, 95% confidence
interval 0.126–0.550; P < 0.001). The median bilirubin level
in the first week after surgery was lower in NMLP recipients
(2.25mg dl−1, 95% confidence interval 1.23–4.28) than in the
SCS group (2.87mg dl−1, 95% confidence interval 1.52–5.00; P
= 0.029). There was no difference in median intensive care unit
stay (P = 0.339) as well as hospital stay (P = 0.926) or the need
for renal replacement therapy in the first postoperative week
(P = 0.621) between the two groups. Graft survival at 1 year
in the NMLP group was 0.950 (95% confidence interval 0.893–
0.977), compared with the SCS 0.960 (95% confidence interval
0.897–0.985) (P = 0.695) (50).
The COPE (Consortium on Organ Preservation in Europe)
project (51, 52) demonstrated significant reductions in peak AST
and EAD rates in NMLP livers. However, it was stated that
a larger trial with a longer follow-up period is mandatory to
establish and assess whether there is a major difference in graft
or patient survival.
Ghinolfi et al. reported the results of 20 livers from donors
70 years old or older randomized with SCS, thus 10 livers were
perfused with NMLP Organ Assist R© (53). The results showed
no PNF in either group. There were two cases of EAD in
NMLP and 1 case in SCS. No differences were observed in
either a post-operative transaminitis or bilirubin peak in the
first 7 post-operative days. In the NMLP arm of the trial, one
graft was lost due to hepatic artery thrombosis, but no other
vascular complications were observed in any other trial patients.
In the SCS group, one patient died due to sepsis. Furthermore,
the researchers performed biopsies and demonstrated that there
was histological evidence of reduced IRI, demonstrated by
a significant decrease in mitochondrial volume density and
intracellular lipid droplets at the end of transplantation in the
NMLP group vs. the SCS group (P < 0.001). All these reports
are summarized in Table 1.
NORMOTHERMIC MACHINE PERFUSION
FOR ORGAN PRESERVATION
As the demand for livers for transplantation grows worldwide,
maximizing graft utilization is paramount. In this setting,
NMLP allows groups to assess the liver viability and to
chronologically evaluate the quality of at-risk grafts requiring
restoration. Evidence shows that NMLP could play a role in
reconditioning and restoring organs such as DCD or steatotic
livers to optimize potentially transplantable liver allografts. The
latter are considered to be grafts from ECDs, especially with
the biopsy-proven macrosteatosis lipid concentration at 30–
40%. In fact, macrosteatotic livers have been shown to have the
poorest graft outcomes in terms of PNF and graft dysfunction,
and consequently many of them are declined. The reason for
this poor function seems to be excessive cytoplasmic fatty
acids, which enhance lipoperoxidation, thus releasing more free
radicals and reactive oxygen species (54). This induces disruption
of cells, releasing PAMPs and DAMPs and therefore triggering
the activation of TLRs (specifically TLR2 and TLR4), RIG-I-
like receptors and NOD-like receptors, which all drive a pro-
inflammatory response (55).
In experimental models, NMLP has been associated with
reduction of triglyceride content as well as increased bile
and urea production, and this process is enhanced with the
TABLE 1 | Outcomes of Normothermic machine perfusion (NMP).















Perera et al. (45) Observational OrganOx metra® DCD 1 vs. 0 365 days: 100% 365 days: 100% NA
Mergental et al. (47) Observational OrganOx metra® DBD+DCD 5 vs. 0 180 days: 100% NA NA
Bral et al. (49) Nonrandomized
pilot study
OrganOx metra® DBD+DCD 10 vs. 30 180 days: 80% vs.
100%
180 days: 89% vs.
100%
1,252 vs. 839
Nasralla et al. (50) RCT OrganOx metra® DBD+DCD 121 vs. 101 365 days: 95% vs.
96%
365 days: 94.9 vs.
95.8%
167.5 vs. 318.5





RCT, randomized controlled trial; DBD, donor brain death; DCD, donor cardiac death; SCS, static cold storage; AST, aspartate aminotransferase.
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implementation of liver defatting protocols (56). NMLP alone in
human steatotic livers did not demonstrate encouraging results;
a Liu et al. study reported that after 24 h of NMLP there was no
reduction in tissue steatosis (57, 58). Pharmacological-induced
defatting feasibility trials have shown some promise in widening
the donor pool. Nagrath et al. reported that after 48 h of NMLP,
administering a defatting cocktail produced a 35% reduction in
the intracellular lipid content within the livers for this model
(59, 60). Other studies of pharmacologically induced defatting
agents during NMLP used 10 mmol of L-carnitine added to the
perfusate in order to improve mitochondrial oxidation of fatty
acids, obtaining a 10% reduction in macrosteatosis (61).
Boteon et al. allocated ten discarded steatotic livers into
two NMLP groups: the treatment group had the perfusate
supplemented with a defatting cocktail, whereas the control
group was without supplementation. The defatting cocktail
reduced tissue triglycerides by 38% and macro-vesicular steatosis
by 40% over 6 h.Moreover, grafts in the defatting group displayed
augmented and improved metabolic functional parameters such
as urea production (P = 0.03), lower release of alanine
aminotransferase (P = 0.049), and higher bile production (P
= 0.008) with a higher bile pH (P = 0.03). Furthermore, the
treatment reduced expression of key markers of IRI as well as
activation of immune cells (CD14- found in neutrophils and
macrophages; CD11b- found in NK cells and macrophages)
and reduced the release of pro-inflammatory cytokines in the
perfusate, particularly TNF-α and IL-1β (62).
NMLP has proven to maximize organ utilization and offer
the opportunity for organ reconditioning and rehabilitation by
circumventing the mechanisms of IRI and their deleterious
consequences to the allograft. Further, the defatting of human
grafts opens the possibility of treating declined steatotic livers
and enhancing their utilization rate. Defatting trials have shown
improvements in hepatic microcirculation, downregulation of
Kupffer cells, and reduced release of inflammatory mediators
during reperfusion, resulting in a reduction in subsequent
reperfusion tissue injury. Although these findings are promising,
rigorous research with clear long-term outcome data is
required before it can be considered a widely accepted clinical
option (63).
IMMUNE RESPONSE AND NMLP
NMLP significantly improves post LT outcomes with a reduction
of the IRI in CIT. NMLP therefore enhances ATP restoration
by decreasing the anaerobic metabolism of cells, leading to
less accumulation of metabolites such as lactate, which affect
the acid-base balance within the hepatic microenvironment
and often enhance proteolytic enzymatic activity and liver
tissue degradation (64). Jassem et al. detailed results regarding
the immune response after NMLP (65). The study matched
12 DBD grafts perfused with NMLP and 27 DBD grafts
preserved with SCS. At the end NMLP or SCS, they performed
serial biopsies pre- and post-reperfusion for both histological
and transcriptomic analysis of the perfusate and parenchyma
from the livers in the study. Intrahepatic lymphocytes were
extracted were recognized to be representative of liver-resident
lymphocytes (66). The group found that in the SCS group there
was a higher level of gene expression of immune-related genes,
in particular pro-inflammatory cytokines, and also increased
expression of genes involved in humoral immunity, platelet
activity and neutrophil chemotaxis, when compared to the
NMLP group. Moreover, several genes linked to the stress
response and cell apoptosis, such as thrombomodulin (THBD)
and IFN-γ, were up-regulated in the SCS cohort but not in the
NMLP livers in the post-reperfusion phase of the study. The
study assessed the effect of NMLP on the differentiation of T
helper cells: Th1 (IL-2, IL-17, IFN-γ), Th2 (IL-4) as well as on
Treg (IL-10 and TGF-β) cytokine production by intrahepatic
CD4+. CD8+ T cells have also shown to secrete cytokines which
effect T cells differentiation. NMLP grafts had significantly lower
amounts of CD4+ T cells producing IL-4 (p < 0.05), IL-2 (p
< 0.001), IFN-γ (p < 0.05), and IL-17 (p < 0.0001). There
were no significant differences found in the production of the
anti-inflammatory, regulatory cytokines IL-10 or Transforming
Growth Factor-Beta (TGF-β). NMLP significantly decreased the
proportions of CD8+ T cells subsets producing IFN-γ (p <
0.001), while slight reductions in IL-17 were also observed. There
were no changes in IL-2 production by CD8+ T cells after
NMLP. Studies have identified that within the perfusate and
liver tissue samples in both NMP and SCS there is a significant
increase in regulatory T helper cells and regulatory cytokines
implementing immune tolerance in liver grafts (65, 67). We also
see a statistically significant abundance of intrahepatic Tregs in
NMP when compared to SCS (4.36% ± 3.27 vs. 1.9% ± 1.8, p
= 0.0156), and in conjunction with the presence of IL-2 this
promotes an expansion and proliferation of the Treg subset. In
regards to the clinical parameters of long-term functionality and
survival of graft measured in the study, the peak AST and peak
INR in the first 7 post-operative days were significantly lower in
the NMLP group compared with the SCS group (p < 0.01 and p
= 0.07, respectively), thus suggesting that the NMLP group had
grafts with a greater functionality and survival probability than
the SCS group (65).
Intrahepatic lymphocyte populations have been identified as
being integral in initiating the innate and adaptive immune
responses. Certain lymphocytes subsets have a varied prevalence
in the NMP and SCS. CD3−CD19+ B cells, CD3+CD4+ T
cells and CD3+CD56+ Natural Killer (NK) T (NKT)-like cells
were statistically similar in the liver tissue and perfusate of both
populations in both NMP and SCS (68). Intrahepatic NK cells
are contributors in acute and chronic allograft rejection and are
a key cell subset in amplifying the inflammatory process. NK
cells were more prevalent in tissue and perfusate from the SCS
samples when compared to NMP samples. NMP livers showed a
significant up-regulation of genes involved in immune-trafficking
compared to SCS in both pre-reperfusion and post-reperfusion
stages. In biopsies collected pre- and post-reperfusion, the
Jassem et al. study demonstrated significantly lower quantities
of apoptotic and necrotic cells in NMLP compared to SCS,
as well as reduced quantities of neutrophil clusters within the
parenchymawhenNMLP livers were comparedwith SCS livers in
both pre- and post-reperfusion stages. The group concluded that
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NMLP minimizes inflammation and cell death, and promotes
liver restoration and regeneration (65).
THE FUTURE OF ORGAN PRESERVATION
Sub-normothermic machine liver perfusion (SNMLP) has
become a prominent technique in preserving livers at lower
temperatures on the perfusion circuit. A research group
stored the human liver graft at −4◦C with the supercooling
method followed by sub-normothermic machine perfusion. This
technique could extend up to 27 h of ex vivo preservation of the
liver, without altering the viability of the organ. In super-cooling
livers, the parenchyma can withstand the stress of simulated
transplantation by ex vivo normothermic reperfusion with blood
(69). The results have shown some promising clinical outcomes
(70, 71).
Other studies like Eshmuminov et al. have attempted to
increase the length of time for reconditioning on NMP and
have demonstrated graft viability on animal models perfused
for 7 days without the need for additional blood products or
perfusate exchange (72). This novel approach was conducted
using ten human livers declined for transplantation. After 7
days of perfusion, 6 out of 10 human livers showed preserved
function as indicated by bile production, synthesis of coagulation
factors, maintained cellular energy (ATP) and an intact liver
structure (72).
The boundaries of NMLP have attempted to be pushed tomeet
the demands of transplantation as well as improving outcomes
of these marginal livers used. The proof of concept study
developed by Wu et al. raises the possibility of an ischaemia-free
organ transplantation (IFOT). In essence, by removing the total
element of IRI by preventing it whilst continually maintaining
the blood supply for the organ at a physiological temperature
throughout the procurement period until implantation, we may
be able to eliminate the threat of graft dysfunction secondary
to IRI. The group maintained NMLP during procurement and
preservation until implantation and the recipient experienced no
post-reperfusion syndrome. Initial investigations including liver
function tests as well as histological analysis demonstrated a low
injury to hepatocytes and vascular and biliary epithelium during
preservation and post-transplantation.Moreover, they stated that
the inflammatory cytokine levels were much lower in IFOT than
those in conventional procedures (73).
Undoubtedly, there is an impending influx of innovative
technologies will open new horizons for organ preservation
and restoration and in return reduce mortality on transplant
waiting lists. Despite clinical trials in the field being in their
infancy, the results so far have been very encouraging with
promising graft and patient outcomes. However, with few
medical governing bodies embracing and introducing machine
perfusion preservation for transplantable organs into their
guidelines, further work in the form of multi-center randomized
controlled trials with a focus on long-term outcome data is
required in order to establish best clinical practice for liver
preservation and restoration.
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